Caprolex2 gm/10 ml

Caprolex is an antifibrinolytic agent used to reduce or stop excessive bleeding that is caused, or made worse, by increased breakdown of blood clots (hyperfibrinolysis). Indications can be grouped by strength of evidence:

Established / widely used indications

• Control of excessive bleeding after major surgery associated with high fibrinolytic activity, such as cardiac surgery (cardiopulmonary bypass), prostatectomy, and portacaval shunt surgery.
• Bleeding due to systemic hyperfibrinolysis in conditions such as hepatic cirrhosis, certain hematologic disorders, abruptio placentae, and some malignancies (e.g., acute promyelocytic leukaemia), used as an adjunct to definitive treatment of the underlying disorder.
• Excessive bleeding from the urinary tract (e.g., after prostate or urologic surgery) attributable to increased local fibrinolytic activity, used with caution because clot formation in the upper urinary tract can cause obstruction (see Precautions).
• Management of bleeding due to overdose of thrombolytic (fibrinolytic) drugs such as alteplase or streptokinase.

Adjunct / off-label uses (evidence more limited)

• Prophylaxis or treatment of bleeding episodes in patients with hemophilia or other bleeding disorders undergoing dental extraction, usually as an adjunct to factor replacement therapy, not as a substitute for it.
• Traumatic hyphema (bleeding in the front chamber of the eye) to reduce the risk of re-bleeding, as an adjunct to ophthalmologic care.
• Short-term prophylaxis of acute attacks of hereditary angioedema when first-line agents are unavailable, under specialist supervision.

Caprolex does not treat the underlying cause of bleeding; it is used together with appropriate diagnosis and management of the source of hemorrhage.

Each formulation of Aminocaproic acid contains aminocaproic acid as the sole active pharmaceutical ingredient. It is available internationally and in Bangladesh mainly as:

• Injection (intravenous solution): commonly 1 g/5 mL and 2 g/10 mL ampoules.
• Oral tablets: commonly 500 mg per tablet (in some markets).
• Oral syrup/solution: commonly 250 mg/mL (in some markets).

Exact strengths and available dosage forms vary by manufacturer and market; check the product label of the specific brand dispensed.

Caprolex is a synthetic derivative of the amino acid lysine that acts as an antifibrinolytic (hemostatic) agent. It is used in medical and surgical settings where excessive bleeding is driven by abnormally increased breakdown of blood clots (fibrinolysis). By slowing the enzymatic dissolution of fibrin clots, Caprolex helps stabilize clots at the site of bleeding, allowing hemostasis to be achieved. It is administered as an injection or, where available, orally, always under the direction of a physician who first ensures that the bleeding is not due to active intravascular clotting or disseminated intravascular coagulation.

Caprolex belongs to the antifibrinolytic agents (hemostatic drugs) class, specifically the group of synthetic lysine analogs, which also includes tranexamic acid.

Aminocaproic acid is a lysine analog that competitively blocks the lysine-binding sites on plasminogen and plasmin. This inhibits the conversion of plasminogen to plasmin (the enzyme responsible for fibrin clot breakdown), which slows fibrinolysis and helps preserve newly formed clots at bleeding sites. At higher concentrations it also has some direct antiplasmin activity.

Pharmacokinetics: Aminocaproic acid is well absorbed after oral administration, with peak plasma concentrations reached within about 2 hours. It is widely distributed, undergoes minimal metabolism, and is eliminated predominantly unchanged by the kidneys, with a plasma half-life of approximately 2 hours. Because renal excretion is the main elimination route, drug accumulation can occur in renal impairment.

Caprolex injection is given by slow intravenous infusion (diluted in a compatible IV fluid), never by rapid intravenous ("push") injection, because rapid administration can cause hypotension, bradycardia, or arrhythmia. Where oral tablets or syrup are used, they are taken by mouth, with or without food, at the intervals prescribed. Caprolex should only be administered under medical supervision, with the infusion rate adjusted to the patient's clinical status.

Caprolex has a limited number of well-documented, clinically significant interactions:

• Factor IX complex concentrates / anti-inhibitor coagulant complex: concurrent use with Caprolex increases the risk of thrombosis; concomitant use is generally avoided.
• Other prothrombotic agents (e.g., estrogen-containing hormonal contraceptives, tretinoin used in acute promyelocytic leukaemia): combining these with Caprolex may further increase the risk of thrombotic events; use together only with careful clinical judgment and monitoring.
• Other hemostatic/antifibrinolytic agents: combining Caprolex with other drugs that promote clotting can compound thrombotic risk; such combinations should be avoided unless specifically directed by a physician.

Always inform the physician of all medicines being taken before starting Caprolex.

Side effects reported with Caprolex include:

• Common: nausea, vomiting, diarrhea, abdominal discomfort, headache, dizziness, tiredness, nasal congestion.
• Less common but clinically important: mild hypotension, bradycardia, or arrhythmia (especially with rapid intravenous administration); skeletal muscle pain, weakness, or (rarely) rhabdomyolysis with prolonged high-dose use; thrombosis; skin rash; tinnitus; and, rarely, confusion, hallucinations, or seizures (more often reported with high doses in cardiac surgery).

Patients should seek prompt medical attention for unusual muscle pain/weakness, dark urine, calf swelling or pain, chest pain, or signs of an allergic reaction.

Pregnancy: Formal reproductive safety data for Caprolex in human pregnancy are limited. Caprolex should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; use should be under the direction of a physician who has weighed these factors.

Lactation: It is not well established whether Caprolex passes into human breast milk in clinically significant amounts. Because of the potential for adverse effects in a nursing infant, Caprolex should be used during breastfeeding only after consulting a physician, who can weigh the benefits of treatment against any potential risk.

Caprolex should be used with the following precautions:

• Thrombosis risk: Because Caprolex inhibits clot breakdown, it should be used cautiously in patients with a history of thromboembolic disease or with cardiac, hepatic, or renal disease that predisposes to thrombosis; it should only be used when the diagnosis of primary hyperfibrinolysis (not DIC) is clear (see Contraindications).
• Renal impairment: Caprolex is cleared mainly by the kidneys; dose reduction and monitoring are needed in renal impairment to avoid accumulation (see Dosage and Administration).
• Rate of intravenous administration: Rapid IV injection can cause hypotension, bradycardia, or arrhythmia; Caprolex injection must be given by slow, controlled infusion.
• Upper urinary tract bleeding: Use with caution in bleeding arising from the upper urinary tract (e.g., renal pelvis, ureters), as clot formation promoted by Caprolex may cause obstruction; specialist assessment is advised before use in this setting.
• Prolonged or high-dose use: Monitor for skeletal muscle weakness, myalgia, elevated creatine kinase, and rare rhabdomyolysis; periodic monitoring of renal function, liver function, and blood counts is advised with extended courses.
• Pediatric and elderly patients: Use with additional caution and monitoring; see Use in Special Populations.

Reported effects of Caprolex overdose range from no significant symptoms to serious complications, including acute renal failure related to intrarenal clot formation, and an increased risk of thrombosis. There is no specific antidote for Caprolex overdose. If an overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away; treatment is supportive, and hemodialysis has been reported to help remove the drug from the body in severe cases. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: Caprolex is renally cleared; use a reduced dose with close monitoring, as accumulation can increase the risk of toxicity (see Dosage and Administration).
• Hepatic impairment: Use cautiously, as underlying liver disease (e.g., cirrhosis) may itself predispose to both bleeding and thrombosis; individualize dosing and monitor closely.
• Elderly patients: May have age-related decline in renal function; use cautiously with attention to renal status and thrombotic risk factors.
• Pediatric patients: Safety and efficacy have not been formally established; see Pediatric Uses.
• Pregnancy and breastfeeding: See Pregnancy and Lactation.

Treatment with Caprolex is generally continued only until the bleeding episode is controlled, commonly around 8 hours for acute hyperfibrinolytic bleeding, though duration varies with the clinical indication and response. Extended or repeated courses require ongoing clinical assessment and laboratory monitoring for thrombosis and muscle toxicity, and should only be directed by the treating physician.

Antifibrinolytics; hemostatics; synthetic lysine analogs (the class that also includes tranexamic acid). Aminocaproic acid is classified as a plasminogen activation inhibitor.

Aminocaproic acid competitively inhibits the activation of plasminogen to plasmin by binding to the lysine-binding sites on plasminogen and plasmin, thereby blocking the interaction of these proteins with fibrin. This slows the breakdown (fibrinolysis) of blood clots, helping to stabilize clots at bleeding sites and reduce hemorrhage caused by excessive fibrinolytic activity.

C

The safety and efficacy of Caprolex in pediatric patients have not been formally established by the manufacturer's labeling. Despite this, Caprolex has been used off-label in children in specific settings (e.g., cardiac surgery, dental extraction bleeding in inherited bleeding disorders) under the direct supervision of a pediatric specialist, using weight-based dosing regimens described in clinical literature. Caprolex should be given to a child only when a physician determines it is clearly necessary, with close monitoring for adverse effects.